ClinicalTrials.gg
Not yet recruitingNCT07949032Updated Nov 19, 2026

Wearable Sensors and Video-Based Testing to Track Arm Function After Treatment for Neurogenic Thoracic Outlet Syndrome

An observational study in Neurogenic Thoracic Outlet Syndrome Thoracic Outlet Syndrome, sponsored by University of California, Los Angeles. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of California, Los Angeles · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The goal of this study is to learn whether wearable motion sensors and video-based movement analysis can track changes in arm function over time in adults with neurogenic thoracic outlet syndrome (NTOS) who are receiving standard treatment (physical therapy or surgery).

NTOS happens when nerves between the neck and shoulder are squeezed, causing pain, numbness, weakness, and trouble using the arm. There is currently no objective test to measure how severe NTOS is or how well treatment is working.

The main questions this study aims to answer are:

  • Can digital measurements of arm movement, collected with wearable sensors and with standard webcam video, detect changes in arm function after NTOS treatment?
  • Are these digital measurements more sensitive to change than standard questionnaires?
  • Do video-based measurements agree with sensor-based measurements?
  • Can measurements taken before treatment help predict who will improve with physical therapy?

This study does not assign or change treatment. Physical therapy or surgery is chosen by each participant's doctors as part of usual care.

Participants will:

  • Complete 5 study visits over about 12 months: before treatment and 1 and 2 months after treatment (in clinic), and 6 and 12 months after treatment (remote telemedicine visits)
  • At each visit, perform a short arm movement task (the "Press Test," a 20-second hand-over-head exercise) while wearing motion sensors and/or being recorded on video
  • Complete questionnaires about arm function, pain, mood, and overall health
Read the detailed description

Neurogenic thoracic outlet syndrome (NTOS) is a disorder of dynamic compression of the brachial plexus between the first rib and the scalene muscles. Diagnosis currently relies on subjective clinical assessment, and there are no objective measures to monitor response to treatment. This study evaluates a remote patient monitoring platform that extracts digital biomarkers of upper extremity motor function from the Press Test, a 20-second repetitive hand-over-head task designed to provoke NTOS symptoms.

This is a single-site, prospective longitudinal study at the UCLA Thoracic Outlet Syndrome Center. Adults with a treating-physician diagnosis of NTOS who are proceeding with standard-of-care treatment (physical therapy and/or surgery) are followed for 12 months. Treatment selection is made by the treating clinicians and is not assigned by the study. Approximately 50 participants undergoing physical therapy and 50 undergoing surgery will be enrolled.

At each of five time points (baseline 0-1 month before treatment; 1, 2, 6, and 12 months after treatment), participants perform the Press Test while digital biomarkers are captured with wearable inertial sensors and with AI-based analysis of standard webcam video. The baseline, 1-month, and 2-month assessments are performed in person; the 6- and 12-month assessments are performed remotely via secure telehealth, with sensors provided in clinic or mailed to the participant with written instructions and staff support. Patient-reported outcomes (DASH, VAS pain, Zung Self-Rating Depression Scale, and PROMIS Global Health) are collected at each time point. Feasibility and acceptability of remote assessment are evaluated through visit completion rates, time burden, technical issues, and a technology acceptance questionnaire.

Analyses will use linear and generalized linear mixed models to assess change over time, intraclass correlation coefficients and Bland-Altman analyses to compare sensor- and video-derived measures, and exploratory models to identify baseline predictors of response to physical therapy.

This study is funded by the National Institutes of Health (R01HD121303).

02

Conditions studied

  • Neurogenic Thoracic Outlet Syndrome Thoracic Outlet Syndrome
03

In context

Thoracic Outlet Syndrome

34 studies on the registry are indexed under Thoracic Outlet Syndrome; 11 are open to participants now.

This study's planned enrollment of 100 is above the median of 84 across 16 observational studies indexed under Thoracic Outlet Syndrome.

Browse Thoracic Outlet Syndrome studies →

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,171 studies on the registry; 195 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Adults aged 18 to 60 years with a treating-physician diagnosis of neurogenic thoracic outlet syndrome who are evaluated at the UCLA Thoracic Outlet Syndrome Center and are proceeding with standard-of-care physical therapy or surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 18 to 60 years
  • Treating-physician diagnosis of neurogenic thoracic outlet syndrome (NTOS)
  • Plan for standard-of-care treatment (physical therapy and/or surgery) at UCLA
  • Right-handed, left-handed, or ambidextrous
  • Able to provide and complete study activities

Exclusion criteria

Exclusion Criteria:

  • Bilateral NTOS
  • Previous surgery for NTOS at any time, or NTOS-directed physical therapy within the past 2 months
  • Venous thoracic outlet syndrome
  • Arterial thoracic outlet syndrome
  • NTOS together with another condition affecting the upper extremity
  • Cognitive impairment
  • Acute or chronic conditions unrelated to NTOS that may affect upper extremity function (e.g., stroke, Parkinson's disease, arthritis, cancer)
  • History of drug or alcohol abuse within the past 6 months
  • Inability to participate in follow-up assessments (e.g., plans to move out of state within 12 months, or inability to complete remote follow-up visits)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Physical Therapy

    Adults with neurogenic thoracic outlet syndrome whose treating physician has recommended standard-of-care physical therapy. Participants complete digital biomarker assessments (Press Test with wearable sensors and webcam video) and patient-reported outcome questionnaires before treatment and at 1, 2, 6, and 12 months after treatment. Treatment is not assigned by the study.

  • Surgery

    Adults with neurogenic thoracic outlet syndrome whose treating physician has recommended standard-of-care surgical decompression (e.g., first rib resection, scalenectomy, and brachial plexus neurolysis). Participants complete digital biomarker assessments (Press Test with wearable sensors and webcam video) and patient-reported outcome questionnaires before treatment and at 1, 2, 6, and 12 months after treatment. Treatment is not assigned by the study.

06

What researchers measure

Primary outcomes

  1. Change in Press Test Digital Biomarkers of Upper Extremity Function

    Digital biomarkers of upper extremity motor function (representing slowness, weakness, rigidity, exhaustion, and unsteadiness, e.g., speed, power, rise time, and range of motion) extracted from a 20-second repetitive hand-over-head Press Test using wearable inertial sensors and AI-based webcam video analysis. Change from baseline will be assessed at each follow-up time point.

    Time frame: Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

  2. Change in Disabilities of the Arm, Shoulder and Hand (DASH) Score

    The DASH is a 30-item self-reported questionnaire of upper extremity disability and symptoms. Scores range from 0 to 100; higher scores indicate greater disability.

    Time frame: Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

Secondary outcomes

  1. Change in Pain Intensity (Visual Analog Scale)

    Self-reported pain intensity on a 0 to 10 visual analog scale; higher scores indicate worse pain.

    Time frame: Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

  2. Change in Zung Self-Rating Depression Scale (SDS) Score

    20-item self-reported depression scale. Raw scores range from 20 to 80; higher scores indicate more severe depressive symptoms.

    Time frame: Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

  3. Change in PROMIS Global Health Physical and Mental Health T-Scores

    PROMIS Global Health v1.2 (10 items) yields Global Physical Health and Global Mental Health T-scores (population mean 50, SD 10); higher scores indicate better health.

    Time frame: Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

  4. Agreement Between Sensor-Based and Video-Based Digital Biomarkers

    Agreement between digital biomarkers derived from wearable sensors and from AI-based webcam video analysis during the Press Test, assessed by intraclass correlation coefficient (ICC) at each time point.

    Time frame: Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

  5. Baseline Digital Biomarkers as Predictors of Response to Physical Therapy

    Performance of machine learning models using pre-treatment digital biomarkers, demographics, and clinical factors to predict non-response to physical therapy (no meaningful symptom improvement), reported as area under the ROC curve (AUC).

    Time frame: Baseline (0-1 month before treatment) and 1, 2, 6, and 12 months after treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2030, 48 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Nov 2030
CompletionEst.
Nov 2031
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07949032
Responsible party
Bryan M. Burt, MD, FACS (Professor and Chief of the Division of Thoracic and Cardiac Surgery at UCLA Health and the David Geffen School of Medicine at UCLA, University of California, Los Angeles) — Principal investigator
First posted
Nov 19, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Nov 2030 (estimated)
Completion
Nov 2031 (estimated)
Last update
Nov 19, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion